Patent CA 25126150

Page 1

I Ofifice de fa p~ropriete Canadian ~ - L~ '~ intelleetuelle Intellectual Property clu Canada Office Un organisme d'Industrie Canada An Agency of Industry Canada Le commissaire au~c brevets a re~u une demande de d€livrance de brevet visant une invention. Ladite requete satisfait awc exigences de la Loi sur les brevets. Le titre et la description de 1'invention figurent dans le memoire descriptif, dont une ~`'~`'' copie fait partie integrante du present F~~ document. ~ ~"~s Le present brevet f~,~ ~ L r=r- . ~' r, r confere a son titulaire eta ~ i >~ ses representants legatix, ~~~: i;` ~ ,~, ~. ~ , pour une p~riode expirant ~,t~,~ i . a , ~ ~;'~~' t `~s2• r'~ f-y. d l j vingt ansa compter de la ~i~4.'~ ~ ~ ~ , ti'. -,~~ +~ ' '.inn f date du depot de la

F,_1`k , ~' ~ ~ ~ ~ ~~ delTlaClC~e all Ca[13d.a~ ~r`~~l,~i~a~l~p~ (~r~~ ~~~ ~~y .~ r f le droit, la faculty et le ~ `°~~' ~ ,`t~`' "~N~ rl ..y~~i ~~i i ~ privilege exclusif de t '''~ " ~ `'' ~`r fabriquer, construire, exploiter }' ~~': ~` et vendre a d'autres, pour qu'ils 1'exploitent, l'objet de 1'invention, saufjugement en 1'espece rendu par un tribunal competent, et sous reserve du paiement des taxes periodiques. The Commissioner of Patents has received a petition.for the grant of a patent for an invention. The requirements of the PatentAct have been complied with. The title and a description of the invention are contained in the specification, a copy of which ~~'~_ ~`~ forms an integral part of this ~`r~ ,;'. document. y The present patent grants

to its owner and to the legal representatives of its owner, for a term which ea~pires twenty years from ,~ the filing date of the application ~` ~ in Canada, the exclusive right, privilege and liberty of mal~ing, constructing and using tr the invention and selling it to others to be used, subject to adjudication before'any court of competent jurisdiction, and subject to the payment of maintenance fees. BREVET CANADIEN 2~5ZC,150 CANADIAN PATENT Date ~ laquelle le brevet a ~t~ 2Qy 4/O5/06 Date on which the patent accords et delivre was granted and issued Date du depot de la demande 2004/06/03 Filing date of the application Date a laquelle la demande est 2005/01/06 Date on which the application devenue accessible au public was made available for pour

consultation public inspection Commissaire awc brevets !Commissioner of Patents ~ --,car sii ~a OPIC `'"" CIPO ~A ~~ 3256(CIPO 91)09/09 -~-'~'u'~9

Page 2

Office de la Propriete Intellectuelle du Canada Un organisme d'Industrie Canada Canadian Intellectual Property Office An agency of Industry Canada 46 ~ pate de depot PCT/PCT Filing Date: 2004/06/03 ~7~ Date publication PCT/PCT Publication Date: 2005/01/06 I5) Date de delivrance/Issue Date: 2014/05/06 d5) Entree phase nationale/National Entry: 2005/11/15 ~s) N° demande PCTlPCT Application No.: US 2004/017567 ~7~ N° publication PCT/PCT Publication No.: 2005/000324 10) Priorite/Priority: 2003/06/03 (US60/475,657) CA 2526150 C 2014/05/06 (11)(21) 2 526 150 ~~2~ BREVET CANADIEN CANADIAN PATENT (13) C, (51) CI.IntJlnt.CL A6~K33/38(2006.01), A6~L 2/00 (2006.01), A6~P 37/04 (2006.01), A69P 37/72 (2006.01), B09J 73/00 (2006.01) (72) Inventeurs/Inventors:

HOLLADAY, ROBERT J., US; CHRISTENSEN, HERBERT, US; MOELLER, WILLIAM D., US (73) Proprietaire/Owner: AMERICAN BIOTECH LABS, US (74) Agent: CASSAN MACLEAN i4) Titre : TRAITEMENT DES HUMAWS AVEC UNE COMPOSITION D'ARGENT COLLOIDALE i4) Title: TREATMENT OF HUMANS WITH COLLOIDAL SILVER COMPOSITION ~7) Abrege/Abstract: oloriess composition comprising silver particles and water, wherein said particles comprise an interior of elemental silver and an exterior of ionic silver oxide, wherein the silver particles are present in the water at a level of about 5-40 ppm, and wherein the omposition manifests significant antimicrobial properties. Methods of use of the composition are described. The composition can to incorporated into a hydrogel with essentially no

loss of antimicrobial properties. Canad'~ ~~~~~opic,gc.ca •Ottawa/Gatineau K1AOC9 • l~ttp.//cipo.gc.ca O P I C ~;~%:~ C I P O ~~~~ OPIC • CIPO 191 ~~~~~

Page 3

CA 02526150 2012-09-05 Treatment of Humans with Colloidal Silver Composition [1] The present application is a continuation -in -part of application 09/946,834, filed September 4, 2001, which is a continuation of application 09/323,310, filed June 1, 1999, now U.S. Patent No. 6,214,299. The present application claims priority to provisional application 60/475,657, filed June 3, 2003. (2] Area of the Art [3] The present invention generally relates to colloidal silver, and more particularly to a composition of colloidal silver and a method for using said composition as an agent against organisms harmful to the health of humans. [4] Description of the Prior Art [5] It is well known that certain preparations of silver have germicidal properties. Silver

was employed as a germicide and an antibiotic before modern antibiotics were developed. In previous centuries, users would shave silver particles into their drinking water, or submerge whole silver pieces in the drinking water, for the purpose of ingesting the silver by drinking the water, It seems likely that the practice of eating with silver utensils (i.e., silverware) resulted from a belief in the healthful properties of silver. [6] There maybe many reasons why administering silver suspended in solution would enhance an individual's health. It is possible that such a solution operates to inhibit the growth of bacteria, viruses, and other unwanted organisms, as well as eradicating such existing bacteria, viruses, and other organisms. It is also

possible that a solution of silver can have an anti-inflammatory effect, sufficient to reduce symptoms of asthma.

Page 4

CA 02526150 2013-07-12 87 WHAT IS CLAIMED IS: 1 A stable, colourless composition of silver in water comprising a total concentration of silver of between about 5 and 40 parts per million, said silver in the form of colloidal silver particles having an interior of elemental silver and a surface of silver oxide, wherein a majority of the colloidal silver particles have a maximum diameter less than 0.015 micrometers, wherein a majority of the colloidal silver particles have a minimum diameter greater than 0.005 micrometers, and wherein the composition manifests antimicrobial properties. 2. The composition according #o claim 1 ,wherein at least 75% of the colloidal particles have diameters between 0.005 micrometers and 0.015 micrometers. 3. The

composition according to claim 2, wherein at least 90% of the colloidal particles have diameters between 0.005 micrometers and 0.015 micrometers. 4. The composition according to claim 3, wherein at least 95% of the coNoidal particles have diameters between 0.005 micrometers and 0.015 micrometers. 5. The composition according to claim 1 ,wherein the colloidal particles have an average diameter of about 0.10 to 0.1 1 micrometers.. 6. The composition according to claim 1 further comprising hydrogen peroxide. 7. The composition according to claim 6, wherein the hydrogen peroxide concentration is between about 1 % wght/v and about 3.0% wght/v. 8. The composition according to claim 1,wherein the composition manifests antimicrobial properties against

microbes selected from the group consisting of Bacillus anthraces, Bacillus subtilis, Candida albicans, Mycobacteria bavis, Mycobacteria tuberculosis, Pseudomonas aeruginosa, Salmonella choleraesius, Staphylococcus aureus, Trichomonas vaginalis, and Yersinia pesos. 9. The composition according to claim 8, wherein Staphylococcus aureus is a methicillin-resistant strain.

Page 6

CA 02526150 2013-07-12 89 20. The composition according to claim 19, wherein the plant gums are selected from the group consisting of xanthan gum, locust bean gum, gum traganth, guar gum, and gum arabic. 21 . The composition according to claim 15 further comprising additives to enhance physical characteristics of the hydrogel and/or enhance wound healing. 22. The composition according to claim 21, wherein the additives are selected from the group consisting of vitamins, amino acids, growth factors, maltodextrin, aloe vera and anesthetics. 23. The composition according to claim 15 further comprising additional antimicrobial agents. 24. The composition according to claim 23 wherein the additional antimicrobial agents are selected from the group

consisting of organic acids, alcohols, organic disinfectants, chlorinated phenolics, chlorhexidine, biguanides, surfactants, aldehydes, halogen disinfectants and axygenatirtg disinfectants. 25. The composition accordingto claim 15 used as a personal lubricant. 26. The composition according to claim 15 used as a disinfectant on diaphragms. 27. An ex vivo method of disinfecting a surface comprising applying the composition according to claims 1 or 15 to said surface. 28. Use of the composition according to claims 1 or 15 for disinfection of human skin. 29. A method of eliminating danger from bacteria in water comprising adding an aliquot of the composition according to claim 1 to said water. 30. Use of the composition of claim 1 for the inhibition of

viral DNA polyme~`ase. 31. Use of the composition of claim 1 for the inhibition of viral reverse transcriptase.

Page 7

CA 02526150 2013-07-12 32. Use of the composition of claim 1 far the treatment of a disease selected from the group consisting of malaria, fungal infections of the skin, bacterial infections of the skin, vaginal infections, urinary tract infections, tonsillitis, pelvic inflammatory disease, pharyngitis, gonorrhea, conjunctivitis, otitis, respiratory tract infections, and nasal infections. 33. Use of the composition of claim 1 for the treatment of HIV. 34. Use of the composition of claim 1 for the treatment of hepatitis B.